Evidence map›Paper›PMID 41965737›Full record

ArticleCancer cell international2026

SETDB1 promotes gastric cancer progression via UPR and mTOR pathway.

Jing Qiao, Shijie Lin, Yeju Li, Xiaoyang Yue, Yanyan Liu, Huajian Tian, Jianshuang Li, Junyang Tan

Abstract read
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing QiaoThe Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, 511518, Guangdong, China.
Shijie LinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China.
Yeju LiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China.
Xiaoyang YueState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China.
Yanyan LiuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China.
Huajian TianState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China.
Jianshuang LiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China.
Junyang TanState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China. junyangtan@jnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SET Domain Bifurcated histone lysine methyltransferase 1 (SETDB1), a histone H3K9 methyltransferase, is frequently overexpressed in multiple malignancies, including gastric cancer (GC). However, its molecular functions and regulatory mechanisms in GC progression remain poorly defined. Here, we identified the role of SETDB1 in gastric cancer using molecular and cell biology methods, combining RNA-seq and RNC-mRNA seq. Here, we found SETDB1 was markedly upregulated in gastric cancer tissues compared with adjacent non‑tumor tissues. Functional analyses revealed that SETDB1 knockdown suppressed GC cell proliferation and migration, whereas overexpression had the opposite effect. Notably, SETDB1 promoted cell proliferation independently of its methyltransferase activity, while its enhancement of migration required enzymatic function. Mechanistically, SETDB1 activated the unfolded protein response (UPR) to stimulate c-MYC transcription and cell-cycle progression, and engaged the mTOR–4EBP1 axis to promote HIF1α translation. These findings reveal a dual regulatory role for SETDB1 in GC and identify it as a promising therapeutic target for managing gastric cancer.

Indexed as

Gastric cancerHistone H3K9 methyltransferaseMTORSETDB1Unfolded protein response

Identifiers

PMID41965737
PMCPMC13214091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.